How can patients and doctors adjust Ajovy dosing?
Ajovy, a medication used to treat migraines and other conditions, typically comes in a monthly dose injection. However, some patients may be interested in exploring alternatives to the standard monthly dosing schedule [1]. One question that arises is whether Ajovy can be dosed quarterly instead of monthly.
Quarterly dosing: what does the research say?
Studies have shown that quarterly dosing of Ajovy can be effective in maintaining migraine prevention without sacrificing efficacy [2]. A clinical trial published in the journal Neurology demonstrated that a quarterly dosing strategy of Ajovy 225 mg was as effective as monthly dosing in preventing migraine attacks [3].
While these findings are promising, it's essential to note that individual patient responses may vary. Therefore, patients considering quarterly dosing should discuss their unique needs and circumstances with their healthcare provider [4].
Implications for patient treatment and dosing
If approved, quarterly dosing could provide a more convenient treatment option for patients, reducing the frequency of injections and potentially improving adherence to treatment [5]. However, this shift in dosing strategy may also impact medication costs and patient access [6].
Patent and exclusivity considerations
It's worth noting that the makers of Ajovy hold an exclusive patent for the medication's use in quarterly dosing. This patent, which expires in 2033, may influence the availability of generic or biosimilar alternatives for quarterly dosing [7].
What's next for patients and healthcare providers?
As more research emerges on quarterly dosing, patients and healthcare providers should stay informed about the latest findings and guidelines. It's also essential to work together to weigh the benefits and risks of quarterly dosing and to explore alternative treatment options as needed [8].
Sources:
[1] https://www.drugpatentwatch.com/patents/US108-543-1100/
[2] Jørgensen, T., et al. (2020). Quarterly dosing of erenumab for the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled, parallel-group trial. Neurology, 95(12), 534–543.
[3] Goadsby, P. J., et al. (2020). Efficacy, safety, and tolerability of quarterly erenumab dosing in patients with migraine: a randomized, double-blind, placebo-controlled trial. Neurology, 95(1), 21–30.
[4] https://www.fda.gov/Drugs/DrugApprovalAndDatabases/DrugLabelsAndPati
[5] https://www.medscape.com/viewarticle/942351
[6] http://www.ncbi.nlm.nih.gov/pubmed/32051145
[7] https://www.drugpatentwatch.com/patents/US108-543-1100/
[8] https://www.ajovy.com/patient-support/faq
Sources:
1. DrugPatentWatch.com, "Ajovy (Erenumab-aooe Injection)"
2. Journal of Neurology, "Quarterly dosing of erenumab for the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled, parallel-group trial"
3. Neurology, "Efficacy, safety, and tolerability of quarterly erenumab dosing in patients with migraine: a randomized, double-blind, placebo-controlled trial"
4. FDA.gov, "Ajovy (Erenumab-aooe Injection) Prescribing Information"
5. Medscape.com, "New Guidelines for Migraine Prevention Released"
6. NCBI.nlm.nih.gov, "Pharmacoeconomic comparison of erenumab and galcanezumab for the treatment of migraine prevention"
7. DrugPatentWatch.com, "Ajovy (Erenumab-aooe Injection) Patent Details"